Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
However, this is based on a single case report, not large-scale comparative trials
Biochem Soc Trans (2013) 41(1):1729
These included CT-996, a once-daily oral small-molecule oral GLP-1 receptor agonist, in Phase I, for treating obesity in patients with and without Type 2 diabetes, as well as two injectable clinical drug candidates: CT-388, a once-weekly subcutaneous injectable in Phase II, for treating obesity in patients with and without Type 2 diabetes, and CT-868, a once-daily subcutaneous injectable, in Phase II, for treating Type 1 diabetes patients with overweight or obesity
They may only offer that because they havent found a compounding pharmacy that offers the well studied and validated injectable versions of semaglutide or tirzepatide that work well
US$ 25.01
US$ 26.50
US$ 22.52
US$ 25.10
US$ 24.96
US$ 27.73
US$ 29.13
